Sabichi is involved in experimental therapeutics of lung, head and neck cancers. She helped investigate a clinical trial involving bevacizumab in the treatment of head and neck cancers. Bevacizumab, also known by brand name Avastin, was recently added to the National Comprehensive Cancer Network’s first-line mesothelioma treatment recommendations.
Sabichi, who has been in practice for more than 20 years, graduated from the University of Colorado School of Medicine. She completed her residency at New York Presbyterian Hospital and her fellowship at the National Institutes of Health Clinical Center.
In 2021, Dr. Sabichi published a research study on anti-PD-1 monotherapy, outlining the clinical benefits as first-line therapy for malignant pleural mesothelioma patients.